Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market Snapshot (2023 to 2033)
The global diamond-blackfan anemia (DBAAASE) syndrome therapeutics market size is expected to surpass an impressive valuation of US$ 4.8 billion in 2023 and is projected to exhibit a CAGR of 4.2% from 2023 to 2033. A valuation of US$ 7.29 billion is expected for the market by the end of the aforementioned period of assessment
Diamond-blackfan anemia is an inherited blood disorder that impairs bone marrow's capacity to generate red blood cells. It is a form of bone marrow malfunction. It is also referred to as obtained pure red cell aplasia and is induced by genetic mutations. Light skin, loss of energy, fast heartbeat, unusual thumbs, low bone density, cleft palate, and heart and kidney difficulties are all symptoms of this disorder. Erythrogenesis imperfecta, DBA, congenital hypoplastic anemia, inherited erythroblastopenia, and congenital pure red cell aplasia is all identities for this condition.
Although most cases are isolated, approximately 45% of people with Diamond-Blackfan anemia inherit the disorder from one of their parents. The increased incidences of diamond-blackfan anemia, burgeoning healthcare expenditure, advancement of therapeutic approaches, soaring federal funding, and surging strategies by government and private organizations to raise illnesses awareness are the aspects that will drive the diamond-blackfan anemia treatment market.
Report Attribute
Details
Expected Market Value (2023)
US$ 4.8 billion
Anticipated Forecast Value (2033)
US$ 7.29 billion
Projected Growth Rate (2023 to 2033)
4.2% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Demand Analysis vs. Forecast 2023 to 2033
Since hematologic complications develop in 90% of infected persons during their first year of life, a rise in the number of blood disorders propelled the global diamond-blackfan anemia treatment market over the historical period. Aplastic anemia is being raised awareness by organizations such as the National Organization for Rare Disorders, Inc. and CancerIndex, among others. The Aplastic Anemia Trust's spring awareness campaign was launched in February 2019.
The pandemic has diminished the number of charitable blood donations and interrupted the global supply chain for medical equipment. Reduced donor inflow, a lack of staff members, a scarcity of blood units, and general concern about transfusion-transmitted COVID-19 were among the major obstacles confronted by blood banks and clinics from 2020 to 2021. From 2018 to 2022, the market witnessed significant growth, registering a CAGR of 3.8%.
Furthermore, rising government support for R&D, changing lifestyles, and rapidly evolving technology are expected to drive market expansion over the forecast period.
Which are Some Prominent Drivers of the DBAAASE Syndrome Therapeutics Market?
Supportive Laws by Government Entities to Spur Market Expansion
The existence of supportive regulations by governmental agencies, such as the Orphan Drug Act, which encourages product development by awarding orphan drug certification to potential drug delivery developed by drug manufacturers, is anticipated to boost industry growth. This initiative promotes study and advancement in the treatment of diamond-blackfan anemia.
According to a recent article, the US Food and Drug Administration has approved approximately 21 to 22 novel drugs and biopharmaceuticals for more than 800 rare disease indications. Furthermore, burgeoning genomics investigations have resulted in the discovery of effective biologic drugs for rare genetic disorders. These aspects have significantly boosted the market for diamond-blackfan anemia treatment.
Find your sweet spots for generating winning opportunities in this market.
Federal Spending on Research, Development and Medical Approaches to drive Market Growth
Increasing government expenditure on research, development, and therapeutic interventions is expected to propel the market's growth in the coming decade. For instance, in India, the National Policy for Rare Diseases, 2021 (the Policy) has been accomplished and publicly disclosed.
According to the provisions envisioned in the National Policy for Rare Diseases, 2021, concerning providing economic assistance to individuals with rare diseases, it is proposed that funding will be offered under the umbrella scheme of RAN, i.e. an amount up to Rs. 20 lakhs (US$ 24,358) only for privileged claimants will be offered by the Central Government. As a result, the market for diamond-blackfan anemias treatment is expected to grow.
What are the Challenges Projected to be Faced by the Market?
High Costs and Complicated Side Effects to Hinder Market Growth
The elevated cost of treatment and complications linked to the disease, such as leukemia, osteosarcoma, acute myeloid leukemia, and myelodysplastic syndrome, will impede overall growth and pose significant challenges to the diamond-blackfan anemia treatment market in the coming years. A stem cell transplant costs more than US$ 290,000. As a consequence, the elevated cost of treatment is inclined to stifle growth in the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Region-Wise Insights
What Makes North America the Largest Market of DBAAASE Syndrome Therapeutics?
Major notable stakeholders, high disposable income to drive the North American market
Owing to the existence of major prominent stakeholders, high expendable income, elevated health expenditures, and a well-established medical industry in this region, North America dominates the diamond-blackfan anemia treatment market. According to a report released by Clevel and Clinic, the DBA Registry of North America, a database with data on individuals who have this disorder, 25% of people with DBA die by the age of 50 from associated medical disorders.
North America will dominate the market in 2021 with a sales revenue of more than 60.0% owing to the high incidence of diseases, sophisticated healthcare infrastructure, and unique product authorizations for diagnosis. Tezepelumab received orphan drug certification from the US FDA in October 2021. Exposure to orphan drugs for diamond-blackfan anemia treatment may enhance patient adherence, thereby broadening the consumer base and elevating industry revenue. North America is expected to hold approximately 40% market share.
Why is Europe Considered a Lucrative Region for the DBAAASE Syndrome Therapeutics Market?
Innovative drugs development to drive the European market
Autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene drug were identified as an orphan medication for the treatment of Diamond-Blackfan anemia in the European Union on November 12, 2021. This means that the developer will receive scientific and regulatory assistance from the EMA to advance their medicine to the point where they can apply for marketing authorization, which will boost the market growth in this region.
DBA UK is a registered charity (1083179) ruled by a written constitution and operated by elected volunteer groups. They provide support, studies, and hope to the DBA community by introducing families together to converse about their experiences, convey the most up-to-date medical records, and raise funds to help those with DBA in the United Kingdom. As a result, this venture is predicted to benefit the European market. The Europe market is expected to expand with a CAGR of 3.7%.
Category-Wise Insights
Which Treatment Segment is Expected to Witness High Demand?
Corticosteroids are among the most widely prescribed Medicine Classes Worldwide
Customers are drawn to corticosteroids because they are available in a variety of forms, including oral capsules or tablets, oral syrups, injectables, topical creams or gels, and nasal sprays.
Corticosteroids are also one of the most frequently prescribed drug classes globally, with a market worth more than US$ 10 billion per year, according to a National Library of Medicine report. As a result of the aforementioned factors, the corticosteroids segment is expected to grow significantly during the forecast period.
What is another Treatment Segment Expected to Grow?
The blood Transfusions Segment is predicted to Expand Quickly
The adoption of advanced molecular systems by market leaders accelerates the transition from test cases and instruments to automated devices. These automated systems have been critical in detecting Transfusion Transmissible Infections (TTIs) in samples taken and can accurately avoid human error during the transfusion method. As a result, the blood transfusions segment is expected to expand rapidly, with a CAGR of 6.9%.
Start-ups Specializing in DBAAASE Syndrome Therapeutics
Prominent start-up players in the anorectal malformation treatment sector are introducing novel and innovative product lines to strengthen their market presence, and the aforementioned start-ups have left no stone unturned. The following are some specific examples of significant t start-ups:
EryPharm is a startup that was founded in 2016. EryPharm entered the market in April 2021 with a sophisticated tech that can generate red blood cells in huge volumes and build innovative blood transfusion sources. The company intends to gain entry into a pilot production phase and expand the production of Cultured Red Blood Cells (cRBC) using Hematopoietic Stem Cells (HSC).
In 2017, Torax Biosciences Limited was established. Torax Biosciences Limited introduced its B2B IVD bulk reagents for latex serology and blood grouping assays to the industry in February 2019. The company intends to supply its distribution network, production facilities, and clinics with visual latex agglutination assay ASO, CRP, and RF, as well as blood grouping assays in FFMU or packed formats.
Market Competition
Key players in the Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics market are Sumitomo Corporation, Johnson & Johnson Private Limited, Novartis AG, Pfizer Inc., Sanofi, Merck KGaA, LEO Pharma A/S, Cipla Inc., GlaxoSmithKline plc, AstraZeneca, Abbott Laboratories and Bayer AG.
AstraZeneca Plc. acquired Alexion Pharmaceuticals, a global biotech company, in July 2021. With this acquisition, the company will be able to enter the market for medicines for rare diseases, marking the start of a new chapter. Furthermore, the acquisition strengthened AstraZeneca's scientific presence in immunology and would allow the company to proceed to pioneer the discovery and creation of medicines for rare disease patients through Alexion's new complement-biology system and sturdy pipeline.
Pfizer Inc. collaborated with Sirana Pharma, a biotechnology company, in June 2022. The collaboration would aid Pfizer in the recognition and affirmation of an innovative treatment notion for rare and severe bone diseases. In addition, the procurement would initially involve the adoption of Sirana's proprietary microRNA approach, which aims for significant restorative recovery of diseased muscle and bone tissue.
Report Scope
Report Attribute
Details
Expected Market Value (2023)
USS 4.8 billion
Anticipated Forecast Value (2033)
US$ 7.29 billion
Projected Growth Rate (2023 to 2033)
4.1% CAGR
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Treatment
End User
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
UK
France
Spain
Italy
China
Japan
South Korea
Singapore
Thailand
Indonesia
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Sumitomo Corporation
Johnson & Johnson Private Limited
Novartis AG
Pfizer Inc.
Sanofi S.A
Merck & Co. Inc.
LEO Pharma A/S
Cipla Limited
GSK Plc.
AstraZeneca Plc.
Abbott Laboratories
Bayer AG
Customization
Available Upon Request
Key Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market Industry Survey
By Treatment:
Corticosteroids
Chelation Therapy
Blood Transfusions
Stem Cell Transplant
Others
By End User:
Hospitals
Clinics
Others
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Frequently Asked Questions
How did the Market Develop in the Past?
The global market exhibited a 3.8% CAGR from 2018 to 2022.
What is the Future Growth Forecast for the Market?
The market is forecast to register a CAGR of 4.2% through 2033.
Which Treatment Segment is Expected to Witness High Demand?
Corticosteroids are among the most widely prescribed medicine classes worldwide.
What is another Treatment Segment Expected to Grow?
The blood transfusions segment is predicted to expand significantly.
What are the Challenges Projected to be Faced by the Market Players?
High costs and complicated side effects are likely to hinder market growth.
Table of Content
1. Executive Summary | Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market
1.1. Global Market Outlook
1.2. Demand to side Trends
1.3. Supply to side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Corticosteroids
5.3.2. Chelation Therapy
5.3.3. Blood Transfusions
5.3.4. Stem Cell Transplant
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 20232033
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. US
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End User
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End User
13.6. UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Sumitomo Corporation
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Johnson & Johnson Private Limited
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Novartis AG
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Pfizer Inc.
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Sanofi
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Merck KGaA
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. LEO Pharma A/S
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Cipla Inc.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. GlaxoSmithKline plc
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. AstraZeneca
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. Abbott
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
15.1.12. Bayer AG
15.1.12.1. Overview
15.1.12.2. Product Portfolio
15.1.12.3. Profitability by Market Segments
15.1.12.4. Sales Footprint
15.1.12.5. Strategy Overview
15.1.12.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by End User, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by End User, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by End User, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by End User, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by End User, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 89: MEA Market Attractiveness by End User, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
